Pravachol Sales Lag In Second Quarter; Bristol Pledges Continued Support
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb will continue to provide "strong support" for its cholesterol-lowering agent Pravachol (pravastatin) as a prescription therapy despite another quarter of declining sales as the drug approaches patent expiration in the U.S
You may also be interested in...
Bristol Sells Its Mead Johnson Adult Nutritionals Business To Novartis
The divestiture of Mead Johnson's adult nutritionals business to Novartis Medical Nutrition will allow the Bristol-Myers Squibb division to concentrate on its infant formula franchise
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands